title: Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
abstract: Angiogenesis plays an important role in many types of cancer. Interleukin-8 (IL-8) is known to be a pro-inflammatory and pro-angiogenic cytokine, and IL-8 has been reported to be associated with tumor progression, prognosis and survival in several types of cancers. However, the role of IL-8 in non-Hodgkin's lymphoma (NHL) has not been fully determined. Here, we evaluated the usefulness of measuring serum and urine IL-8 levels in patients with NHL. We developed reference intervals for serum and urine IL-8 level in 131 control individuals. We measured serum IL-8 and urine IL-8 levels in patients with NHL, and we compared the concentrations with those of control individuals. The reference intervals for serum IL-8 and urine IL-8 corrected by creatinine (Cr) were 15.9-430.3 pg/mL and 0.0-28.4 pg/mg Cr, respectively. The concentrations of urine IL-8/Cr were significantly higher in patients than in controls (48.9+/-194.4 vs. 5.2+/-13.8 pg/mg Cr, P<0.001). However, there were no significant differences in serum IL-8 concentrations between NHL patients and controls (159.2+/-40.4 vs. 99.6+/-107.1 pg/mL; P=0.099). Receiver operating characteristic (ROC) analysis gave 0.83 and 0.43 ROC area values for urine IL-8/Cr and serum IL-8, respectively. There was no correlation between the serum and urine concentrations of IL-8 and clinical variables, the only exception being the international prognostic index (IPI), which showed a marginal correlation with urine IL-8/Cr levels (P=0.07). This study indicated that urine IL-8/Cr levels might be useful as a diagnostic marker of NHL.
authors.affiliation: Hematologic Malignancies Branch, Division of Translational & Clinical Research II, Research Institute & Hospital, National Cancer Center, 809 Madu-dong, Ilsan-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.
authors.forename: Hye Lin
authors.initials: HL
authors.lastname: Lee
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
authors.forename: Tak
authors.initials: T
authors.lastname: Yun
authors.forename: Hyun-Ju
authors.initials: HJ
authors.lastname: Kim
authors.forename: Weon-Seo
authors.initials: WS
authors.lastname: Park
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Nam
authors.forename: Seong
authors.initials: S
authors.lastname: Moon-Woo
authors.forename: Do-Hoon
authors.initials: DH
authors.lastname: Lee
authors.forename: Sun-Young
authors.initials: SY
authors.lastname: Kong
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000652:urine*; D003404:Creatinine / Q000097:blood / Q000592:standards / Q000652:urine; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood* / Q000592:standards / Q000652:urine*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000175:diagnosis / Q000652:urine*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012074:Remission Induction
chemical_list: D014408:Biomarkers, Tumor; D016209:Interleukin-8; D003404:Creatinine